766 results on '"Januzzi, James L Jr"'
Search Results
2. Heart Failure Drug Development Over the Eras: From the Heart Failure Collaboratory
3. Racial Differences in Diabetic Cardiomyopathy: The ARISE-HF Trial
4. Randomized Trial of a Selective Aldose Reductase Inhibitor in Patients With Diabetic Cardiomyopathy
5. Associations between lipoprotein(a), oxidized phospholipids, and extracoronary vascular disease
6. Vascular endothelial growth factors and risk of cardio-renal events: Results from the CREDENCE trial
7. 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee
8. Early Longitudinal Change in Heart Failure Health Status Following Initiation of Canagliflozin
9. Sex Differences in Coronary Artery Disease Characteristics Among Patients With Type 2 Myocardial Infarction
10. Efficacy, Safety and Mechanistic Impact of a Heart Failure Guideline-Directed Medical Therapy Clinic
11. Natriuretic Peptides and Prognosis in Patients With Type 2 Diabetes Mellitus and High Risk for Cardiovascular Events
12. Morbidity and Mortality Associated With Heart Failure in Acute Coronary Syndrome: A Pooled Analysis of 4 Clinical Trials
13. Association Between Wearable Device Measured Activity and Patient-Reported Outcomes for Heart Failure
14. Polypharmacy and Optimization of Guideline-Directed Medical Therapy in Heart Failure: The GUIDE-IT Trial
15. Coronary Computed Tomographic Angiography With Fractional Flow Reserve in Patients With Type 2 Myocardial Infarction
16. Impact of SGLT2 Inhibitors on AF Recurrence After Catheter Ablation in Patients With Type 2 Diabetes
17. Clinical outcomes associated with type II myocardial infarction caused by bleeding
18. Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations
19. Effect of 2022 ACC/AHA/HFSA Criteria on Stages of Heart Failure in a Pooled Community Cohort
20. Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure: A Scientific Statement From the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society
21. Clinical profiling of end-stage heart failure with preserved ejection fraction: The National Readmission Database
22. Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases
23. Rationale and design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure Trial (ARISE-HF) in patients with high-risk diabetic cardiomyopathy
24. Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria
25. Dose-Response to Sacubitril/Valsartan in Patients With Heart Failure and Reduced Ejection Fraction
26. Endovascular Baroreflex Amplification With the MobiusHD Device in Patients With Heart Failure and Reduced Ejection Fraction: Interim Analysis of the First-in-Human Results
27. Cardiovascular Disease Projections in the United States Based on the 2020 Census Estimates
28. Prognostic Implications of N-Terminal Pro–B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-Preserved
29. Precision Phenotyping of Dilated Cardiomyopathy Using Multidimensional Data
30. Frailty, Guideline-Directed Medical Therapy, and Outcomes in HFrEF: From the GUIDE-IT Trial
31. Using Artificial Intelligence to Better Predict and Develop Biomarkers
32. Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin
33. Diagnosis and Management of Acute Heart Failure
34. How to Ace Cardiology and the Boards Including What to Review
35. Cost and Value in Contemporary Heart Failure Clinical Guidance Documents
36. Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial
37. Hospitalizations and Outcomes of T1MI Observed Before and After the Introduction of MI Subtype Codes
38. NT-proBNP for Risk Prediction in Heart Failure: Identification of Optimal Cutoffs Across Body Mass Index Categories
39. Gaining Efficiency in Clinical Trials With Cardiac Biomarkers: JACC Review Topic of the Week
40. Discordance of High-Sensitivity Troponin Assays in Patients With Suspected Acute Coronary Syndromes
41. A Test in Context: Interpretation of High-Sensitivity Cardiac Troponin Assays in Different Clinical Settings
42. Cardiovascular Risk Factors Are Associated With Future Cancer
43. Patient Characteristics and Clinical Outcomes of Type 1 Versus Type 2 Myocardial Infarction
44. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee
45. Cause of Death in Patients With Acute Heart Failure: Insights From RELAX-AHF-2
46. Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium
47. Finding a Needle in a Haystack: Proteomics in Heart Failure
48. Early clinical and sociodemographic experience with patients hospitalized with COVID-19 at a large American healthcare system
49. Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk
50. Diagnostic and Prognostic Utilities of Insulin-Like Growth Factor Binding Protein-7 in Patients With Dyspnea
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.